GlassScriptPhysician profile
Cheryl A Stroot
NPI 1427571785
$589.88
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $355 · 2022: $144 · 2023: $90.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $178.61 | 2021-2023 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $60.61 | 2021 | |
| Insmed, INC. | $47.27 | 2021-2023 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $40.94 | 2022-2023 | Opsumit |
| Glaxosmithkline, LLC. | $35.46 | 2021-2022 | |
| Electromed, INC. | $33.68 | 2021 | |
| Mallinckrodt Hospital Products INC. | $32.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.24 | 2021 | |
| Inspire Medical Systems, INC. | $28.01 | 2023 | Inspire |
| Vanda Pharmaceuticals INC. | $27.38 | 2022 | |
| Amgen INC. | $25.71 | 2022 | |
| Mylan Specialty L.P. | $18.72 | 2021 | |
| Shionogi INC | $15.87 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Stroot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.